Clinical Trials Directory

Trials / Unknown

UnknownNCT04821102

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy in Patients With K-L Grade III Knee Osteoarthritis After JOINTSTEM Administration

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
21 (estimated)
Sponsor
R-Bio · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to confirm cartilage regeneration through arthroscopy after a single administration of autologous Adipose Tissue derived Mesenchymal stem cells(JOINTSTEM) in patients with degenerative arthritis of K-L grade 3

Detailed description

JOINTSTEM is injectables for an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is cultured without additional genetic modification, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection. It primarily aims to regenerate cartilage. The intra-articular injection of JOINTSTEM is expected to stimulate the regeneration of cartilage, and to innovatively improve joint function with cartilage regeneration. The subjects of this therapy were patients with K\&L grade 3 aged 20 or older. This study is a double-blind, randomized, placebo controlled study with two arms to evaluate JOINTSTEM as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 21 patients will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 placebo control). After each patient completes 12-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

Conditions

Interventions

TypeNameDescription
BIOLOGICALJOINTSTEMJOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
DRUGSalinesaline, 1 time injection under ultrasonic guided

Timeline

Start date
2023-07-01
Primary completion
2024-08-01
Completion
2024-12-31
First posted
2021-03-29
Last updated
2022-09-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04821102. Inclusion in this directory is not an endorsement.